Press Release

7th September 2026 BSE Limited (‘BSE’) National Stock Exchange of India Limited Listing Department Exchange Plaza, C-1, Block G, Corporate Relationship Department B andra Kurla Complex Phiroze Jeejeebhoy Towers Bandra (E), Mumbai — 400 051 2nd Floor, Dalal Street Symbol: MOLBIO Mumbai – 400 001 BSE Script Code: 544866 Subject: Press Release on Unaudited Financial Results for the quarter ended June 30, 2026 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of other applicable laws, if any, please find enclosed the Press Release on Unaudited Financial Results for the quarter ended June 30, 2026. This intimation is also available on the Company’s website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is for your information, records and appropriate dissemination. Thanking you. For and on behalf of Molbio Diagnostics Limited Darshan Raghunath Karekar Company Secretary & Compliance Officer M. No: F13569 Place: Verna-Goa EARNINGS PRESS RELEASE Molbio Diagnostics reports Q1 FY27 performance, with continued momentum in Truenat test-kit volume ▸ Total Income stood at ₹411.48 Cr ▸ EBITDA at ₹103.68 Cr against a loss of ₹14.50 Cr in Q1 FY26; EBITDA Margin at 25.20% ▸ PAT at ₹ 52.74 Cr against a loss of ₹23.94 Cr in Q1 FY26; PAT Margin at 12.82% Goa, India, 7th September 2026: Molbio Diagnostics Limited (NSE: MOLBIO; BSE: 544866), an innovative point- of-care diagnostics company, announced its financial results for the quarter ended June 30, 2026, following the Company's listing on August 17, 2026. Consolidated Financial Highlights (In ₹ Crore) Particulars Q1 FY27 Q1 FY26 Q4 FY26 Total Income* 411.48 100.47 565.41 EBITDA* 103.68 (14.50) 163.51 EBITDA Margin (%) 25.20% (14.43%) 28.92% PAT 52.74 (23.94) 95.83 PAT Margin (%) 12.82% (23.83%) 16.95% *Total Income & EBITDA includes other income Key Financial & Operational Highlights  Q1 FY27 Total Income stood at ₹411.48 Cr as against ₹100.47 Cr in Q1 FY26, driven by continued volume of Truenat test-kit consumption  Q1 FY27 EBITDA stood at ₹103.68 Cr as against ₹ (14.50) Cr in Q1 FY26 with EBITDA Margin at 25.20% vs. (14.43%) in Q1 FY26. Margin trajectory reflects operating leverage on rising test-kit volumes, partly offset by continued investment in international go-to-market build-out  Q1 FY27 PAT stood at ₹52.74 Cr as against ₹ (23.94) Cr in Q1 FY26, with PAT Margin at 12.82%. Key Operating Metrics KPIs Q1 FY27 Q1 FY26 Q4 FY26 Truenat devices sold (Units) 164 216 1,158 Truenat test kits sold (Mn Units) 6.24 0.79 5.38 Domestic revenue mix (%) 83.52% 81.84% 93.97% Export revenue mix (%) 16.48% 18.16% 6.03% Management Commentary Commenting on the performance, Mr. Sriram Natarajan, Executive Director & Chief Executive Officer, Molbio Diagnostics Limited, said: "FY27 is a milestone year for Molbio, marking our transition to a listed company. I would like to thank our shareholders, employees, customers and partners for the trust they have placed in Molbio through our recent listing, and we remain committed to delivering on that trust through consistent execution. I am pleased to report that we have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1. However, our business continues to have a non-linear revenue profile, with performance varying across quarters. We therefore believe it is important to assess our performance on a full-year basis. During the quarter, certain export orders pertaining to Q4 FY26, amounting to approximately ₹ 57 crore, were deferred due to the prevailing situation in the Gulf and were subsequently recognised in Q1 FY27. Total Income for Q1 FY27 stood at ₹411.48 Cr, with EBITDA at ₹103.68 Cr against a loss of ₹14.50 Cr in Q1 FY26. Growth continues to be led by test-kit consumption across the 12,500+ Truenat® devices sold in 90+ countries. We entered FY27 with meaningful capacity headroom - FY26 device and test-kit utilisation at 42% and 58%, respectively, positioning us for volume-led scale-up without near-term incremental capex. Our pipeline of 34 additional assays across 22 diseases remains on track and will be a key long-term driver as we extend beyond infectious disease into oncology and other non-communicable areas. Internationally, we are deepening our presence across Africa and Southeast Asia, entering Latin America, and progressing regulatory pathways in developed markets, including CE-IVDR for our CTNG Test. Following our listing on August 17, 2026, deployment of the net issue proceeds is underway across capex for automation and building our R&D facility in Bengaluru. We remain focused on disciplined execution, sustained R&D intensity and improving cash flow quality as our international and acquired businesses scale." About Molbio Diagnostics Limited Molbio Diagnostics Limited (NSE: MOLBIO; BSE: 544866), is an innovative point-of-care diagnostics company headquartered in Goa, focused on expanding access to accurate, rapid and cost-effective diagnostic solutions for infectious and non-communicable diseases. Its flagship innovation, the Truenat® platform, is a novel, portable and battery-operated real-time PCR platform designed to enable decentralised molecular testing, including in resource- limited settings, with results available in about an hour. Protected by patents in more than 100 countries, Truenat® supports molecular testing for 30 diseases through 43 assays, including tuberculosis, COVID-19, Hepatitis B and C, HIV and HPV. Molbio's tuberculosis test is among only two rapid molecular diagnostic platforms globally endorsed by the World Health Organization (WHO) for the initial detection of tuberculosis and rifampicin resistance. As of March 31, 2026, more than 12,500 Truenat® devices have been installed in 90+ countries. The Company has also expanded its product portfolio and entered areas including radiology, digital pathology and breast health screening through subsidiaries - Prognosys Medical Systems and OptraScan Inc. and strategic partnerships with UE Lifesciences. For further information, please contact Molbio Diagnostics Limited Adfactors PR Pvt. Ltd. Runjun Dutta Janhavi Bellare Head – Communications +91 93228 54508 runjun.dutta@molbiodiagnostics.com janhavi.bellare@adfactorspr.com Smit Shah/ Anand Venugopal +91 9870789596 / +91 7021852071 smit.shah@adfactorspr.com anand.venugopal@adfactorspr.com